Fig. 2 | npj Precision Oncology

Fig. 2

From: ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

Fig. 2

A multi-institutional, randomized clinical trial of patients with recurrent platinum-resistant epithelial ovarian cancer was initiated to assess the efficacy of chemotherapy regimens selected by the ChemoID assay vs. best physician choice. Chemotherapy drugs and doses used in the trial are indicated. The primary endpoint of this trial was objective response rate (ORR). Secondary endpoints were Progression-Free Survival (PFS), duration of response (DOR), measurement of CA125 serum levels, and health-related quality of life.

Back to article page